Bioxytran (BIXT) Accounts Payables (2010 - 2026)
Bioxytran (BIXT) posted Accounts Payables of $1.1 million for Q1 2026, up 25.41% sequentially from $849636.0 in Q4 2025, and up 91.71% YoY from $555792.0 in Q1 2025.
Bioxytran (BIXT) Accounts Payables (2010 - 2026) Analysis & Trends
Bioxytran has reported Accounts Payables for 17 years, with the latest figure at $1.1 million in Q1 2026.
- Quarterly Accounts Payables rose 91.71% year-over-year to $1.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.1 million (up 91.71% YoY) and the FY2025 annual result came in at $849636.0, up 205.34% from the prior year.
- Accounts Payables rose to $1.1 million in Q1 2026 per BIXT's latest filing, from $849636.0 in the prior quarter.
- Over five years, Accounts Payables peaked at $1.1 million in Q1 2023 and troughed at $22948.0 in Q2 2025.
- A 5-year average of $463703.4 and a median of $352572.0 in 2023 frame the typical range for Accounts Payables.
- The sharpest annual moves came in 2024 and 2025: Accounts Payables plunged 91.14% in 2024, then jumped 469.51% in 2025.
- Over 5 years, Accounts Payables stood at $753824.0 in 2022, then slumped by 59.85% to $302681.0 in 2023, then dropped by 8.07% to $278258.0 in 2024, then surged by 205.34% to $849636.0 in 2025, then gained by 25.41% to $1.1 million in 2026.
- According to Business Quant data, Accounts Payables over the past three periods registered $1.1 million, $849636.0, and $322457.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 167.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 470.30 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 108.02 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 428.93 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 35.57 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 622.65 Mn |
| 10 | Bioxytran | 2.47 Mn | 2.22 Mn | - | 1.20 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.07 Mn |
| Dec 31, 2025 | 849,636.00 |
| Sep 30, 2025 | 322,457.00 |
| Jun 30, 2025 | 22,948.00 |
| Mar 31, 2025 | 555,792.00 |
| Dec 31, 2024 | 278,258.00 |
| Sep 30, 2024 | 98,426.00 |
| Jun 30, 2024 | 105,252.00 |
| Mar 31, 2024 | 97,591.00 |
| Dec 31, 2023 | 302,681.00 |
| Sep 30, 2023 | 352,572.00 |
| Jun 30, 2023 | 562,662.00 |
| Mar 31, 2023 | 1.10 Mn |
| Dec 31, 2022 | 753,824.00 |
| Sep 30, 2022 | 341,511.00 |
| Jun 30, 2022 | 556,835.00 |
| Mar 31, 2022 | 516,139.00 |
| Dec 31, 2021 | 624,316.00 |
| Sep 30, 2021 | 248,218.00 |
| Jun 30, 2021 | 151,420.00 |